This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Roche Holding AG
Drug Names(s): Zalcitabine, ddC
Description: Hivid (Zalcitabine, ddC) is a synthetic pyrimidine nucleoside analogue active against the human immunodeficiency virus (HIV). Zalcitabine is a synthetic nucleoside analogue of the naturally occurring nucleoside deoxycytidine, in which the 3'-hydroxyl group is replaced by hydrogen. Within cells, zalcitabine is converted to the active metabolite, dideoxycytidine 5'-triphosphate (ddCTP). ddCTP inhibits the activity of the HIV-reverse transcriptase both by competing for utilization of the natural substrate, deoxycytidine 5'-triphosphate (dCTP), and by its incorporation into viral DNA.
Pink Sheet Roche To Stop Selling Early HIV Drug HIVID
Pink Sheet Monotherapy with Roche's Hivid
Pink Sheet Roche's Hivid
Pink Sheet Roche’s Hivid
Additional information available to subscribers only: